Immunocore Q3 2025 KIMMTRAK sales $103.7M, up 29% YoY; net loss $0.2M vs profit $8.7M

Immunocore Holdings plc

2025-Q3 EPS reported -$0.11 revenue$295,538,000

KIMMTRAK net revenue $103.7M (Q3); $295.5M YTD, up 31% YoY; US sales $67.3M, Europe $33.5M.
Net loss $(0.2)M vs profit $8.7M in Q3 2024; diluted EPS $(0.00) vs $0.17.
IDMC recommended 160 mcg dose for brenetafusp in Phase 3 PRISM-MEL-301; on track to complete enrollment in 1H 2026.
Cash, equivalents & marketable securities $892.4M as of Sept 30, 2025; expects $65M rebate payments in Q4.
Phase 3 TEBE-AM (tebentafusp) enrollment on track for 1H 2026 completion; multiple pipeline programs advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.